Advances in pancreatic islet transplantation for the treatment of type 1 diabetes have occurred in the past decade. Successful transplantation using the Edmonton protocol has achieved glycemic stability and insulin independence in many recipients. However, the effect of islet transplantation on secondary complications of diabetes is still not clearly understood. The UBC Islet Transplant Program is involved in a study to address this issue by comparing outcomes in transplant recipients with outcomes in patients receiving current best medical management of type 1 diabetes. Future research needs to involve improving islet yield, islet engraftment, immunosuppression regimens, and donor supply.
A new study underway at the UBC Islet Transplant Program may help determine the effect of pancreatic islet cell transplantation on the secondary complications of type 1 diabetes
The success of pancreatic islet transplantation using the Edmonton protocol is a significant landmark in patient care and research in the search for a cure for type 1 diabetes (T1D). It is estimated that there are approximately 20 to 26 new cases of T1D per 100 000 children aged 0 to 14 years in Canada each year.
The state of complete insulin deficiency seen in T1D is associated with hyperglycemia and long-term secondary complications involving the kidneys, eyes, nerves, and blood vessels. It has been clearly established that tight blood sugar control reduces the likelihood of developing secondary complications from diabetes. Unfortunately, tight blood sugar control with insulin therapy may not prevent all serious complications of diabetes and is associated with increased frequency of hypoglycemia. The Diabetes Control and Complications Trial (DCCT) findings published in 1993 unequivocally showed that aggressive insulin therapy resulting in near normoglycemia leads to a decreased risk of eye, kidney, and nerve disease when compared with standard insulin treatment. This tighter glucose control was, however, associated with an increased rate of hypoglycemia.
Currently, best medical therapy includes more than intensive insulin treatment alone. It includes blood pressure control, blood cholesterol control, and use of protective medications such as angiotensin converting enzyme (ACE) inhibitors. However, even with current best medical therapy, diabetes complications still occur and diabetes has become the leading cause of blindness and kidney disease in adults. The disease often disables people in their middle years and people with diabetes are known to die younger than those not affected.
Pancreatic islet transplantation is a new treatment now being tested as an alternative to conventional medical therapy for T1D. Pancreatic islet cells, which can sense blood sugar levels and release the appropriate amount of insulin, can be transplanted to achieve precise glycemic control. Recent successes reported in some programs have enabled islet transplant recipients to stop insulin therapy for more than 1 year. This has sparked worldwide interest in the further development and study of islet transplantation to treat diabetes. Although promising, it is not known if islet transplantation is better, safer, or more cost-effective than current best medical therapy for diabetes.
According to the International Islet Transplant Registry, several studies in human islet transplantation were attempted in the 1990s, totaling 47 human islet transplants at 79 institutions worldwide. The majority of these transplants were combined kidney-islet grafts performed with standard combined immunosuppression using anti-thymocyte globulin, glucocorticoids, azathioprine, and cyclosporin. The results of human islet transplant trials prior to 2000 were generally disappointing, with combined 1-year insulin independence rates reported at less than 10%. Fortunately, significant progress has since been made in immunosuppression therapy and islet cell isolation. Using these advances, the Edmonton protocol, published in 2000, showed that islet transplantation was possible for selected patients with labile diabetes using a glucocorticoid-free immunosuppression regimen. The University of Alberta has reported a total of 53 consecutive T1D patients who have received at least one islet transplant as of June 2003. Regarding the three primary indications for islet transplantation, most recipients demonstrated hypoglycemia unawareness (92%), many had lability of blood glucose (51%), and some had progression of secondary complications despite optimal medical therapy (8%). The 1-year rate of sustained insulin independence for all recipients transplanted under the Edmonton protocol has been reported as 80%.
Islet tissue for transplantation is procured from cadaveric donors. The technique of islet isolation requires a well-preserved pancreas with a cold preservation time of less than 8 hours, pancreatic duct cannulation and infusion with collagenase, and continuous digestion of the organ in an automated chamber that allows liberation of the islets from the surrounding exocrine tissue. The islets are subjected to in vitro tissue culture for up to 48 hours, thus allowing the transplant to be performed under elective conditions. The patient is admitted the night before the procedure. During the procedure the patient is sedated and the islets are transplanted through the portal vein, which is accessed through a percutaneous transhepatic catheterization procedure undertaken in the radiology department. Post-transplant, patients are observed on an inpatient unit for approximately 24 hours before discharge from hospital, with follow-up in outpatient clinics.
Very few patients with T1D can be treated at the current rates of organ donation and islet isolation. As a result, we must be able to identify who will benefit most from this limited resource. The islet transplant program in Edmonton has treated T1D patients with hypoglycemia unawareness, brittle control, and a history of frequent, severe hypoglycemic reactions. In this group, the main benefit identified is the achievement of normoglycemia and consequent improved quality of life. Other groups of patients still need to be identified and studied to determine if and how they benefit from islet transplantation.
In patients who have received pancreas transplants, advanced retinopathy does not appear to regress, but the effect on early stages of retinopathy is not currently known. Recurrent nephropathy in transplanted kidneys can be prevented by pancreas transplantation, and reversal of established nephropathy in patients without uremia who received pancreas transplants alone has been observed. Diabetic peripheral neuropathy can be improved, and reduced cardiovascular morbidity and mortality in recipients of successful kidney-pancreas versus kidney-alone transplants is suggested.
Known risks of islet transplantation from the Edmonton experience include procedural and immunosuppression-related complications. Procedural complications arise from percutaneous transhepatic cannulation of the portal vein with islet cell injection. These complications include pain, bleeding, portal vein thrombosis, and abnormal liver function tests. Immunosuppression-related complications include mouth ulcers, nausea, vomiting, diarrhea, increased creatinine, hypertension, dyslipdemia, acne, oily skin, thin nails, rash, headache, tremor, confusion, myalgia, anemia, leukopenia, thrombocytopenia, vitreous hemorrhage, and arthralgia. In addition, long-term risks of transplantation and immunosuppression in general include infection and malignancy.
The effects of pancreatic islet transplantation on the long-term complications of diabetes are not entirely clear. The UBC islet transplant study is currently recruiting an initial cohort of patients who have some degree of retinopathy and microalbuminuria. Through this study we hope to determine if there is any difference in the progression of microvascular complications whether diabetes patients are managed with the principles of best medical therapy or with islet transplantation.
Based on the Edmonton experience, we expect that a first transplant will decrease a patient’s insulin requirements, either partially or completely. A second or third transplant may be required to receive the number of islets needed to allow insulin independence. Each additional transplant will be similar to the first. The timing of additional transplants will depend on the availability of the donated organs. At this time, a total of 24 islet transplant procedures have been performed in 12 patients.
The outcomes from this study will give us important information on the effectiveness and cost of current best medical care compared with islet transplantation for patients with T1D. Consequently, this study is of significant importance in determining not only the status of our current best medical treatment for diabetes, but in providing a benchmark for assessing the efficacy and safety of new diabetes treatments.
The indications for islet transplantation are not generally agreed upon, and it is unclear which patients benefit the most from transplantation. The association of insulin independence with more than one transplant procedure for each recipient remains a major limiting factor. Research is needed to find ways to improve islet yield and islet engraftment, and to develop new immunosuppression regimens that improve islet survival and function.
Limitations in donor supply of islets also remains a barrier to islet transplantation. Estimates suggest there are approximately 400 to 450 cadaveric donors per year in Canada. In future, cell sources such as stem cells may become an alternative to cadaveric sources.
Despite these limitations and uncertainties, continued progress in the area of pancreatic islet transplantation demonstrates the potential of cell replacement therapy for the treatment of diabetes and its secondary complications.
Islet transplant study accepting patients
The UBC islet transplant study is currently accepting patients who meet the following inclusion and exclusion criteria:
In this study we will compare the management of type 1 diabetes in the Islet Transplant Program and the Medical Care Program. The objective of this study is to determine whether there is a difference between programs in preventing diabetes complications. You will be working closely with the diabetes physicians at Vancouver Hospital to manage your diabetes while waiting for a transplant, and with the transplant physicians after you receive an islet transplant. You will also need to be available at very short notice for a transplant.
If you are interested and think that you might qualify:
If you are not interested or do not qualify for a transplant but would like to participate in another aspect of this study that measures the needs and health care costs in all people with type 1 diabetes, please contact us.
For more information, phone Ms Sharon Kozak at (604) 875-5997.
1. Shapiro A, Lakey J, Ryan E, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000;343:230-238. PubMed Abstract Full Text
2. Diabetes Division, Bureau of Cardio-Respiratory Diseases and Diabetes, Laboratory Centre for Disease Control, Health Protection Branch, Health Canada. Diabetes in Canada: National statistics and opportunities for improved surveillance, prevention, and control. Ottawa: Health Canada; 1999. Table of Contents Full Text
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986. PubMed Abstract Full Text
4. Diabetes in America. 2nd ed. Washington, DC: National Diabetes Data Group, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; 1995.
5. Ryan E, Lakey R, Paty B, et al. Successful islet transplantation: Continued insulin reserve provides long-term glycemic control. Diabetes 2002;51:2148-2157. PubMed Abstract Full Text
6. Brendel M, Hering B, Schultz A, et al. International Islet Transplant Registry Report. Giessen, Germany: University of Giessen; 1999.
7. Bretzel R, Brandhorst D, Brandhorst H, et al. Improved survival of intraportal pancreatic islet cell allografts in patients with type-1 diabetes mellitus by refined peritransplant management. J Mol Med 1999;77:140-143. PubMed Citation Full Text
8. Paty B. Islet transplantation. In: Goldfine IO, Rushakoff RJ (eds). Diabetes and Carbohydrate Metabolism. www.endotext.com/diabetes/diabetes9b/diabetesframe9b.htm (accessed 30 August 2004).
9. Ramsay R, Goetz F, Sutherland D, et al. Progression of diabetic retinopathy after pancreas transplantation for insulin-dependent diabetes mellitus. N Engl J Med 1998;318:208-214. PubMed Abstract
10. Bilous R, Mauer S, Sutherland D, et al. The effects of pancreas transplantation on the glomerular structure of renal allografts in patients with insulin-dependent diabetes. N Engl J Med 1989;321:80-85. PubMed Abstract
11. Fioretto P, Steffes M, Sutherland D, et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998;339:69-75. PubMed Abstract Full Text
12. Muller-Felber W, Landgraf R, Scheuer R, et al. Diabetic neuropathy 3 years after successful pancreas and kidney transplantation. Diabetes 1993;42:1482-1486. PubMed Abstract
13. La Rocca E, Fiorina P, di Carlo V, et al. Cardiovascular outcomes after kidney-pancreas and kidney-alone transplantation. Kidney Int 2001;60:1964-1971. PubMed Abstract Full Text
Michelle Fung, MD, FRCPC, David Thompson, MD, FRCPC, and Garth Warnock, MD, FRCSC
Dr Fung is clinical instructor in the Division of Endocrinology at UBC and an endocrinologist at Vancouver Hospital. Dr Thompson is a clinical assistant professor and head in the Division of Endocrinology at UBC. Dr Warnock is professor and head in the Department of Surgery at UBC.
Above is the information needed to cite this article in your paper or presentation. The International Committee
of Medical Journal Editors (ICMJE) recommends the following citation style, which is the now nearly universally
accepted citation style for scientific papers:
Halpern SD, Ubel PA, Caplan AL, Marion DW, Palmer AM, Schiding JK, et al. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.
About the ICMJE and citation styles
The ICMJE is small group of editors of general medical journals who first met informally in Vancouver, British Columbia, in 1978 to establish guidelines for the format of manuscripts submitted to their journals. The group became known as the Vancouver Group. Its requirements for manuscripts, including formats for bibliographic references developed by the U.S. National Library of Medicine (NLM), were first published in 1979. The Vancouver Group expanded and evolved into the International Committee of Medical Journal Editors (ICMJE), which meets annually. The ICMJE created the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals to help authors and editors create and distribute accurate, clear, easily accessible reports of biomedical studies.
An alternate version of ICMJE style is to additionally list the month an issue number, but since most journals use continuous pagination, the shorter form provides sufficient information to locate the reference. The NLM now lists all authors.
BCMJ standard citation style is a slight modification of the ICMJE/NLM style, as follows:
- Only the first three authors are listed, followed by "et al."
- There is no period after the journal name.
- Page numbers are not abbreviated.
For more information on the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, visit www.icmje.org